OpenEvidence Targets Hospitals to Expand Its AI Chatbot for Doctors

In just four years, OpenEvidence has transformed from a promising startup to a tech giant with a $12 billion valuation, all by building a free AI chatbot that doctors love. The platform, which offers evidence-based guidance for clinical decisions, has attracted around 650,000 active U.S. Physicians, particularly trainees who find it invaluable in their daily practice. But as the company faces growing competition and scrutiny over its ad-supported business model, OpenEvidence is looking to expand its reach by targeting hospital systems.

At the STAT Breakthrough Summit West in San Francisco, Zachary Ziegler, Ph.D., co-founder and chief technology officer of OpenEvidence, made a compelling case for why hospitals should embrace their technology. "We’re not crazy monsters," Ziegler said, addressing concerns about data privacy and the company’s business practices. "We understand the importance of trust in healthcare, and we’re committed to building solutions that benefit both clinicians and patients."

Navigating Hospital Skepticism

Hospitals have traditionally been cautious when it comes to adopting new technologies, especially those involving sensitive patient data. OpenEvidence's direct-to-clinician approach has allowed them to bypass the often lengthy and bureaucratic hospital procurement process, but now they face a different challenge: convincing hospital administrators that their platform is not only safe but also valuable.

One of the key selling points for OpenEvidence is its ability to provide real-time, evidence-based guidance to doctors. This can lead to more consistent and high-quality care, which is especially important in complex cases where time is of the essence. Ziegler emphasized that the company's chatbot is not meant to replace doctors but to support them by providing quick access to the latest medical research and best practices.

However, hospitals are also concerned about data security and patient privacy. OpenEvidence has been transparent about its ad-based model, which some critics argue could influence clinical decisions. Ziegler addressed these concerns head-on, stating that the company has strict guidelines in place to ensure that ads do not interfere with the clinical content provided by the chatbot.

"We have a clear separation between our advertising and our clinical guidance," Ziegler said. "Our priority is always the well-being of patients, and we will continue to invest in robust security measures to protect their data."

What Comes Next

As OpenEvidence looks to expand into hospital systems, it will need to build strong partnerships with key stakeholders, including hospital administrators, IT departments, and patient advocacy groups. The company's success will depend on its ability to demonstrate tangible benefits for both clinicians and patients while addressing concerns about data privacy and business practices.

Ziegler is optimistic about the future. "We believe that by working closely with hospitals, we can create a more integrated and efficient healthcare system," he said. "Our technology has already made a significant impact on individual doctors, and we are excited to see what it can do at a larger scale."

The journey ahead will be challenging, but OpenEvidence is well-positioned to continue its growth and innovation in the rapidly evolving landscape of health tech. As hospitals increasingly recognize the potential of AI in improving patient care, OpenEvidence's pitch may just be the key to unlocking a new era of healthcare collaboration.